| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Hyperplasia | 40 | 2016 | 531 | 3.570 |
Why?
|
| Erectile Dysfunction | 26 | 2019 | 452 | 2.060 |
Why?
|
| Prostatitis | 22 | 2011 | 102 | 1.420 |
Why?
|
| Urination Disorders | 14 | 2011 | 241 | 1.160 |
Why?
|
| Adrenergic alpha-Antagonists | 12 | 2008 | 174 | 1.080 |
Why?
|
| Pelvic Pain | 13 | 2010 | 298 | 0.950 |
Why?
|
| Urinary Retention | 5 | 2023 | 107 | 0.930 |
Why?
|
| Urology | 16 | 2020 | 424 | 0.850 |
Why?
|
| 5-alpha Reductase Inhibitors | 7 | 2016 | 117 | 0.760 |
Why?
|
| Sexual Dysfunction, Physiological | 9 | 2016 | 351 | 0.750 |
Why?
|
| Penile Erection | 6 | 2006 | 100 | 0.670 |
Why?
|
| Azasteroids | 5 | 2007 | 37 | 0.660 |
Why?
|
| Peritoneal Neoplasms | 6 | 2024 | 706 | 0.640 |
Why?
|
| Orthopoxvirus | 1 | 2018 | 11 | 0.620 |
Why?
|
| Ejaculation | 8 | 2007 | 59 | 0.610 |
Why?
|
| Finasteride | 5 | 2016 | 90 | 0.610 |
Why?
|
| Oncolytic Virotherapy | 3 | 2018 | 515 | 0.600 |
Why?
|
| Phosphodiesterase Inhibitors | 7 | 2007 | 214 | 0.570 |
Why?
|
| Hyperthermia, Induced | 5 | 2018 | 415 | 0.570 |
Why?
|
| Testicular Diseases | 2 | 2014 | 73 | 0.550 |
Why?
|
| Hospitals, Public | 1 | 2018 | 201 | 0.540 |
Why?
|
| Piperazines | 9 | 2009 | 2520 | 0.520 |
Why?
|
| Colorectal Neoplasms | 5 | 2024 | 6855 | 0.520 |
Why?
|
| Cholecystectomy | 1 | 2018 | 406 | 0.510 |
Why?
|
| Urologic Diseases | 6 | 2005 | 247 | 0.510 |
Why?
|
| Lymph Node Excision | 3 | 2018 | 1305 | 0.500 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2018 | 243 | 0.500 |
Why?
|
| Alprostadil | 3 | 2005 | 86 | 0.480 |
Why?
|
| Cystitis, Interstitial | 3 | 2008 | 66 | 0.470 |
Why?
|
| Prostatism | 3 | 2008 | 14 | 0.460 |
Why?
|
| Community Health Centers | 1 | 2018 | 453 | 0.460 |
Why?
|
| Enzyme Inhibitors | 6 | 2009 | 3726 | 0.450 |
Why?
|
| Prostatic Neoplasms | 23 | 2023 | 11341 | 0.450 |
Why?
|
| Quality of Life | 30 | 2024 | 13300 | 0.430 |
Why?
|
| Intestine, Small | 2 | 2016 | 1207 | 0.430 |
Why?
|
| Out-of-Hospital Cardiac Arrest | 3 | 2022 | 347 | 0.430 |
Why?
|
| Hospitals, Teaching | 1 | 2018 | 1166 | 0.420 |
Why?
|
| Brachytherapy | 8 | 2014 | 1240 | 0.420 |
Why?
|
| Yohimbine | 2 | 2002 | 62 | 0.420 |
Why?
|
| Rectal Neoplasms | 2 | 2024 | 1151 | 0.420 |
Why?
|
| Intestinal Obstruction | 1 | 2016 | 435 | 0.420 |
Why?
|
| Penile Induration | 2 | 2002 | 16 | 0.410 |
Why?
|
| Coitus | 4 | 2006 | 131 | 0.410 |
Why?
|
| Sulfones | 9 | 2009 | 447 | 0.410 |
Why?
|
| Infarction | 1 | 2013 | 248 | 0.400 |
Why?
|
| Neoadjuvant Therapy | 3 | 2024 | 2811 | 0.400 |
Why?
|
| Angiomyolipoma | 1 | 2013 | 184 | 0.400 |
Why?
|
| Male | 157 | 2024 | 359413 | 0.370 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2018 | 3584 | 0.360 |
Why?
|
| Self Concept | 5 | 2007 | 1037 | 0.360 |
Why?
|
| Infertility, Male | 3 | 2020 | 396 | 0.360 |
Why?
|
| Hematuria | 2 | 2011 | 233 | 0.350 |
Why?
|
| Hypogonadism | 3 | 2023 | 800 | 0.350 |
Why?
|
| Penile Prosthesis | 3 | 2019 | 33 | 0.350 |
Why?
|
| Middle Aged | 113 | 2024 | 220175 | 0.350 |
Why?
|
| Radiography, Thoracic | 1 | 2016 | 1295 | 0.340 |
Why?
|
| Pancreatic Neoplasms | 3 | 2021 | 5333 | 0.340 |
Why?
|
| Cardiopulmonary Resuscitation | 3 | 2022 | 1004 | 0.330 |
Why?
|
| Neuroendocrine Tumors | 3 | 2021 | 649 | 0.330 |
Why?
|
| Liver Neoplasms | 2 | 2021 | 4317 | 0.320 |
Why?
|
| Humans | 187 | 2024 | 760261 | 0.320 |
Why?
|
| Phenylpropanolamine | 1 | 2008 | 15 | 0.310 |
Why?
|
| Cresols | 1 | 2008 | 26 | 0.310 |
Why?
|
| Sexual Dysfunctions, Psychological | 3 | 2016 | 189 | 0.310 |
Why?
|
| Health Status Indicators | 6 | 2008 | 968 | 0.300 |
Why?
|
| Purines | 9 | 2009 | 601 | 0.300 |
Why?
|
| Patient Care Team | 2 | 2018 | 2510 | 0.300 |
Why?
|
| Muscarinic Antagonists | 1 | 2008 | 138 | 0.290 |
Why?
|
| Aged | 89 | 2024 | 168995 | 0.290 |
Why?
|
| Adrenergic alpha-1 Receptor Antagonists | 2 | 2009 | 24 | 0.280 |
Why?
|
| Stomach Neoplasms | 3 | 2024 | 1423 | 0.280 |
Why?
|
| Urinary Bladder Neoplasms | 4 | 2011 | 2277 | 0.280 |
Why?
|
| Libido | 5 | 2006 | 119 | 0.270 |
Why?
|
| Genetic Testing | 2 | 2022 | 3530 | 0.260 |
Why?
|
| Emergency Medical Services | 3 | 2022 | 1927 | 0.260 |
Why?
|
| SEER Program | 4 | 2021 | 1532 | 0.250 |
Why?
|
| Doxazosin | 4 | 2006 | 18 | 0.250 |
Why?
|
| Penile Diseases | 2 | 2020 | 45 | 0.250 |
Why?
|
| Prostate-Specific Antigen | 11 | 2023 | 2528 | 0.250 |
Why?
|
| Retrospective Studies | 29 | 2024 | 80301 | 0.240 |
Why?
|
| Insurance, Physician Services | 1 | 2004 | 23 | 0.240 |
Why?
|
| Hysterectomy, Vaginal | 1 | 2024 | 38 | 0.240 |
Why?
|
| Sexuality | 3 | 2001 | 170 | 0.240 |
Why?
|
| Laparoscopy | 4 | 2024 | 2155 | 0.230 |
Why?
|
| Patient Satisfaction | 10 | 2010 | 3451 | 0.230 |
Why?
|
| Urethral Obstruction | 2 | 2003 | 56 | 0.230 |
Why?
|
| Rectum | 4 | 2014 | 896 | 0.230 |
Why?
|
| Tomography, X-Ray Computed | 9 | 2018 | 20484 | 0.230 |
Why?
|
| Wounds and Injuries | 1 | 2016 | 2477 | 0.220 |
Why?
|
| Transurethral Resection of Prostate | 4 | 2006 | 85 | 0.220 |
Why?
|
| Urinary Incontinence | 4 | 2007 | 496 | 0.220 |
Why?
|
| Adult | 72 | 2024 | 219847 | 0.220 |
Why?
|
| Laparotomy | 2 | 2016 | 468 | 0.220 |
Why?
|
| Severity of Illness Index | 12 | 2017 | 15827 | 0.210 |
Why?
|
| Liability, Legal | 1 | 2004 | 210 | 0.210 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3086 | 0.210 |
Why?
|
| Kidney Neoplasms | 3 | 2021 | 4312 | 0.210 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3206 | 0.200 |
Why?
|
| Lithotripsy | 2 | 2002 | 142 | 0.200 |
Why?
|
| Gastrectomy | 2 | 2024 | 677 | 0.190 |
Why?
|
| Watchful Waiting | 2 | 2024 | 510 | 0.190 |
Why?
|
| Infusions, Intra-Arterial | 1 | 2021 | 221 | 0.190 |
Why?
|
| Benzhydryl Compounds | 1 | 2008 | 942 | 0.190 |
Why?
|
| Infusion Pumps, Implantable | 1 | 2021 | 157 | 0.190 |
Why?
|
| Feasibility Studies | 5 | 2022 | 5201 | 0.190 |
Why?
|
| Andrology | 1 | 2020 | 11 | 0.180 |
Why?
|
| Microsatellite Instability | 1 | 2024 | 715 | 0.180 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 2 | 2017 | 92 | 0.180 |
Why?
|
| Penile Neoplasms | 1 | 2002 | 162 | 0.180 |
Why?
|
| Hepatic Artery | 1 | 2021 | 230 | 0.180 |
Why?
|
| Female | 57 | 2024 | 391011 | 0.180 |
Why?
|
| Postoperative Complications | 8 | 2017 | 15680 | 0.180 |
Why?
|
| Ureteral Calculi | 2 | 1999 | 116 | 0.170 |
Why?
|
| Penile Implantation | 1 | 2019 | 12 | 0.170 |
Why?
|
| Scrotum | 1 | 2020 | 116 | 0.170 |
Why?
|
| Prostate | 8 | 2023 | 1793 | 0.170 |
Why?
|
| Cerebral Palsy | 1 | 2024 | 471 | 0.170 |
Why?
|
| Carcinoma, Merkel Cell | 1 | 2024 | 321 | 0.170 |
Why?
|
| Prosthesis Failure | 1 | 2005 | 1206 | 0.170 |
Why?
|
| Hemangiosarcoma | 1 | 2002 | 218 | 0.170 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 2020 | 102 | 0.170 |
Why?
|
| Cryosurgery | 1 | 2004 | 473 | 0.160 |
Why?
|
| Enteral Nutrition | 2 | 2016 | 781 | 0.160 |
Why?
|
| Sulfonamides | 3 | 2006 | 1973 | 0.160 |
Why?
|
| Intestinal Neoplasms | 1 | 2021 | 311 | 0.160 |
Why?
|
| Renal Colic | 1 | 2018 | 28 | 0.160 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2024 | 615 | 0.160 |
Why?
|
| Job Satisfaction | 1 | 2002 | 539 | 0.160 |
Why?
|
| Parapoxvirus | 1 | 2017 | 2 | 0.150 |
Why?
|
| Length of Stay | 4 | 2024 | 6472 | 0.150 |
Why?
|
| Treatment Outcome | 23 | 2024 | 64947 | 0.150 |
Why?
|
| Hormone Replacement Therapy | 1 | 2023 | 756 | 0.150 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2018 | 366 | 0.150 |
Why?
|
| Urologic Surgical Procedures | 1 | 2000 | 310 | 0.150 |
Why?
|
| Internship and Residency | 1 | 2018 | 5867 | 0.150 |
Why?
|
| Acid-Base Imbalance | 1 | 2017 | 41 | 0.140 |
Why?
|
| Health Priorities | 1 | 2020 | 376 | 0.140 |
Why?
|
| Health Care Surveys | 2 | 2004 | 2434 | 0.140 |
Why?
|
| Testosterone | 3 | 2023 | 2469 | 0.140 |
Why?
|
| Aged, 80 and over | 26 | 2017 | 58947 | 0.140 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2021 | 240 | 0.140 |
Why?
|
| Health Care Rationing | 1 | 2020 | 435 | 0.140 |
Why?
|
| Chimera | 1 | 2018 | 453 | 0.140 |
Why?
|
| Hypothermia | 1 | 2018 | 188 | 0.140 |
Why?
|
| Jejunostomy | 1 | 2016 | 59 | 0.140 |
Why?
|
| Mesentery | 1 | 2017 | 203 | 0.140 |
Why?
|
| Sexual Behavior | 5 | 2007 | 2080 | 0.140 |
Why?
|
| Luciferases | 1 | 2018 | 716 | 0.130 |
Why?
|
| Sexual Partners | 4 | 2007 | 750 | 0.130 |
Why?
|
| Double-Blind Method | 13 | 2021 | 12412 | 0.130 |
Why?
|
| Carbolines | 2 | 2010 | 288 | 0.130 |
Why?
|
| Urodynamics | 4 | 2016 | 350 | 0.130 |
Why?
|
| Cholecystectomy, Laparoscopic | 1 | 2018 | 231 | 0.130 |
Why?
|
| Medical History Taking | 4 | 2004 | 773 | 0.130 |
Why?
|
| Incidence | 7 | 2021 | 21378 | 0.130 |
Why?
|
| Axilla | 1 | 2018 | 618 | 0.130 |
Why?
|
| Fecal Incontinence | 2 | 2017 | 242 | 0.130 |
Why?
|
| Waiting Lists | 1 | 2020 | 754 | 0.130 |
Why?
|
| Methyltestosterone | 1 | 1995 | 19 | 0.130 |
Why?
|
| Adenocarcinoma | 3 | 2011 | 6310 | 0.130 |
Why?
|
| Deamino Arginine Vasopressin | 1 | 2015 | 87 | 0.130 |
Why?
|
| Quinazolines | 3 | 2008 | 1363 | 0.130 |
Why?
|
| Neuroma, Acoustic | 2 | 2013 | 455 | 0.130 |
Why?
|
| Appendiceal Neoplasms | 1 | 2017 | 155 | 0.120 |
Why?
|
| Intracranial Hemorrhage, Traumatic | 1 | 2015 | 54 | 0.120 |
Why?
|
| Breast Neoplasms | 2 | 2022 | 21065 | 0.120 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2020 | 576 | 0.120 |
Why?
|
| Sigmoid Neoplasms | 1 | 2015 | 54 | 0.120 |
Why?
|
| Managed Care Programs | 2 | 1999 | 939 | 0.120 |
Why?
|
| Temporal Bone | 2 | 2013 | 683 | 0.120 |
Why?
|
| Practice Guidelines as Topic | 4 | 2020 | 7468 | 0.120 |
Why?
|
| Thromboembolism | 1 | 2021 | 1016 | 0.120 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2019 | 464 | 0.120 |
Why?
|
| Chronic Disease | 18 | 2010 | 9283 | 0.120 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2018 | 1351 | 0.120 |
Why?
|
| Cardiovascular System | 1 | 2021 | 850 | 0.110 |
Why?
|
| Calculi | 1 | 2014 | 49 | 0.110 |
Why?
|
| California | 1 | 2018 | 1416 | 0.110 |
Why?
|
| Fluid Therapy | 1 | 2017 | 593 | 0.110 |
Why?
|
| Lymphedema | 1 | 2020 | 525 | 0.110 |
Why?
|
| Anastomosis, Surgical | 1 | 2017 | 983 | 0.110 |
Why?
|
| Fibroma | 1 | 2015 | 190 | 0.110 |
Why?
|
| Triage | 1 | 2020 | 982 | 0.110 |
Why?
|
| Urinary Tract | 1 | 1997 | 309 | 0.110 |
Why?
|
| United States | 26 | 2024 | 72363 | 0.110 |
Why?
|
| Thrombocytopenia | 1 | 2021 | 1174 | 0.110 |
Why?
|
| Pelvis | 2 | 2017 | 743 | 0.110 |
Why?
|
| Skin Neoplasms | 2 | 2024 | 5797 | 0.100 |
Why?
|
| Platelet Transfusion | 1 | 2015 | 294 | 0.100 |
Why?
|
| Male Urogenital Diseases | 2 | 2005 | 48 | 0.100 |
Why?
|
| Seminoma | 1 | 2013 | 134 | 0.100 |
Why?
|
| Leukocytosis | 1 | 2013 | 251 | 0.100 |
Why?
|
| Orchiectomy | 2 | 2013 | 470 | 0.100 |
Why?
|
| Radiation Injuries | 3 | 2012 | 1183 | 0.100 |
Why?
|
| Diagnosis, Differential | 5 | 2014 | 12968 | 0.100 |
Why?
|
| Alopecia | 1 | 2016 | 415 | 0.100 |
Why?
|
| Lung Neoplasms | 1 | 2016 | 13249 | 0.100 |
Why?
|
| Organs at Risk | 1 | 2014 | 358 | 0.100 |
Why?
|
| Cohort Studies | 11 | 2021 | 41317 | 0.100 |
Why?
|
| Prostatectomy | 5 | 2005 | 1956 | 0.100 |
Why?
|
| Nocturia | 1 | 2011 | 18 | 0.100 |
Why?
|
| Program Development | 1 | 2018 | 1297 | 0.100 |
Why?
|
| Renal Artery | 1 | 2013 | 368 | 0.100 |
Why?
|
| Catheters, Indwelling | 1 | 2014 | 429 | 0.100 |
Why?
|
| Societies, Medical | 10 | 2016 | 3903 | 0.090 |
Why?
|
| Trauma Centers | 1 | 2016 | 934 | 0.090 |
Why?
|
| Pneumonia | 1 | 2022 | 2138 | 0.090 |
Why?
|
| Interdisciplinary Communication | 1 | 2016 | 934 | 0.090 |
Why?
|
| Cardiovascular Diseases | 5 | 2024 | 15740 | 0.090 |
Why?
|
| Necrosis | 2 | 2013 | 1612 | 0.090 |
Why?
|
| Immunotherapy | 2 | 2024 | 4637 | 0.090 |
Why?
|
| Autoantibodies | 2 | 2011 | 2119 | 0.090 |
Why?
|
| Melanoma | 2 | 2020 | 5695 | 0.090 |
Why?
|
| Microspheres | 1 | 2013 | 785 | 0.090 |
Why?
|
| Receptors, Androgen | 1 | 2016 | 1075 | 0.090 |
Why?
|
| Virus Replication | 1 | 2018 | 2431 | 0.090 |
Why?
|
| Clinical Trials as Topic | 3 | 2017 | 8058 | 0.090 |
Why?
|
| Radiography, Abdominal | 1 | 2013 | 532 | 0.090 |
Why?
|
| Urography | 3 | 2008 | 312 | 0.090 |
Why?
|
| Malnutrition | 1 | 2016 | 638 | 0.090 |
Why?
|
| Logistic Models | 6 | 2016 | 13311 | 0.090 |
Why?
|
| Phosphodiesterase 5 Inhibitors | 1 | 2010 | 103 | 0.090 |
Why?
|
| Radiosurgery | 2 | 2013 | 1343 | 0.080 |
Why?
|
| Disinfectants | 1 | 2011 | 130 | 0.080 |
Why?
|
| Lymph Nodes | 2 | 2020 | 3491 | 0.080 |
Why?
|
| Follow-Up Studies | 10 | 2024 | 39254 | 0.080 |
Why?
|
| Sickness Impact Profile | 1 | 2010 | 298 | 0.080 |
Why?
|
| Faculty, Medical | 1 | 2018 | 1192 | 0.080 |
Why?
|
| Cystoscopy | 4 | 2008 | 134 | 0.080 |
Why?
|
| Medicare | 2 | 2024 | 6771 | 0.080 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2018 | 1162 | 0.080 |
Why?
|
| Pain | 1 | 2024 | 5066 | 0.080 |
Why?
|
| Fluoroscopy | 1 | 2013 | 943 | 0.080 |
Why?
|
| Hemorrhage | 1 | 2021 | 3604 | 0.080 |
Why?
|
| Adaptation, Psychological | 4 | 2007 | 2628 | 0.080 |
Why?
|
| Surgical Wound Infection | 1 | 2018 | 1529 | 0.080 |
Why?
|
| Androgens | 1 | 2016 | 1289 | 0.080 |
Why?
|
| Patient Selection | 2 | 2020 | 4276 | 0.080 |
Why?
|
| Epidemiologic Methods | 3 | 2009 | 1344 | 0.080 |
Why?
|
| Disinfection | 1 | 2011 | 209 | 0.080 |
Why?
|
| Ireland | 3 | 2022 | 172 | 0.080 |
Why?
|
| Cochlear Implants | 1 | 1993 | 338 | 0.080 |
Why?
|
| Parenteral Nutrition | 1 | 2013 | 651 | 0.080 |
Why?
|
| Radiation Protection | 1 | 2012 | 425 | 0.080 |
Why?
|
| Neoplasm Invasiveness | 1 | 2016 | 3618 | 0.080 |
Why?
|
| Sensitivity and Specificity | 5 | 2018 | 14656 | 0.080 |
Why?
|
| American Heart Association | 2 | 2024 | 1081 | 0.080 |
Why?
|
| Venous Thromboembolism | 1 | 2021 | 1866 | 0.080 |
Why?
|
| Receptor, erbB-2 | 1 | 2018 | 2544 | 0.080 |
Why?
|
| Angiography | 1 | 2013 | 1605 | 0.080 |
Why?
|
| Personal Satisfaction | 4 | 2007 | 643 | 0.070 |
Why?
|
| Respiration, Artificial | 2 | 2016 | 2623 | 0.070 |
Why?
|
| Brain Stem | 1 | 1993 | 857 | 0.070 |
Why?
|
| Neoplasm Staging | 4 | 2024 | 11141 | 0.070 |
Why?
|
| Ischemia | 1 | 2016 | 1893 | 0.070 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2022 | 3223 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 7 | 2007 | 10340 | 0.070 |
Why?
|
| Testicular Neoplasms | 1 | 2014 | 800 | 0.070 |
Why?
|
| Salvage Therapy | 1 | 2014 | 1266 | 0.070 |
Why?
|
| Vision Screening | 1 | 2008 | 69 | 0.070 |
Why?
|
| Vasodilator Agents | 2 | 2009 | 977 | 0.070 |
Why?
|
| Preoperative Care | 1 | 2016 | 2255 | 0.070 |
Why?
|
| Hydrogen Peroxide | 1 | 2011 | 732 | 0.070 |
Why?
|
| 3-Oxo-5-alpha-Steroid 4-Dehydrogenase | 2 | 2007 | 70 | 0.070 |
Why?
|
| Aging | 3 | 2003 | 8641 | 0.070 |
Why?
|
| Neoplasm Metastasis | 2 | 2016 | 4891 | 0.070 |
Why?
|
| Immunity, Humoral | 1 | 2011 | 604 | 0.070 |
Why?
|
| Triazines | 1 | 2009 | 310 | 0.070 |
Why?
|
| Ciprofloxacin | 2 | 2004 | 312 | 0.070 |
Why?
|
| Radiation Dosage | 2 | 2013 | 1957 | 0.070 |
Why?
|
| Age Factors | 5 | 2018 | 18415 | 0.070 |
Why?
|
| Dihydrotestosterone | 1 | 2007 | 195 | 0.070 |
Why?
|
| Phenotype | 1 | 2024 | 16543 | 0.070 |
Why?
|
| Decision Making | 1 | 2020 | 3924 | 0.070 |
Why?
|
| Prazosin | 1 | 2006 | 95 | 0.070 |
Why?
|
| Dehydroepiandrosterone Sulfate | 1 | 2007 | 240 | 0.070 |
Why?
|
| Polyethylene Glycols | 1 | 2012 | 1188 | 0.070 |
Why?
|
| Multivariate Analysis | 8 | 2021 | 12156 | 0.070 |
Why?
|
| Esophageal Neoplasms | 1 | 2016 | 1651 | 0.070 |
Why?
|
| Massage | 1 | 2006 | 86 | 0.070 |
Why?
|
| Ultrasonography | 3 | 2014 | 5960 | 0.070 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2015 | 1151 | 0.070 |
Why?
|
| Drug Therapy, Combination | 3 | 2006 | 6499 | 0.070 |
Why?
|
| Time Factors | 8 | 2016 | 40133 | 0.070 |
Why?
|
| Isoelectric Focusing | 1 | 2005 | 160 | 0.060 |
Why?
|
| Survival Rate | 4 | 2024 | 12806 | 0.060 |
Why?
|
| Tissue Donors | 1 | 2015 | 2314 | 0.060 |
Why?
|
| Ovarian Neoplasms | 1 | 2022 | 4875 | 0.060 |
Why?
|
| Multicenter Studies as Topic | 2 | 2007 | 1723 | 0.060 |
Why?
|
| Single-Blind Method | 2 | 2013 | 1577 | 0.060 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2005 | 283 | 0.060 |
Why?
|
| Health Surveys | 7 | 2011 | 4061 | 0.060 |
Why?
|
| Gastrointestinal Hemorrhage | 2 | 2003 | 1130 | 0.060 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2021 | 11708 | 0.060 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2014 | 1660 | 0.060 |
Why?
|
| Drug Synergism | 1 | 2009 | 1755 | 0.060 |
Why?
|
| Urination | 2 | 2016 | 202 | 0.060 |
Why?
|
| Prevalence | 9 | 2014 | 15687 | 0.060 |
Why?
|
| Tissue and Organ Harvesting | 2 | 2015 | 377 | 0.060 |
Why?
|
| Cross Infection | 2 | 2011 | 1434 | 0.060 |
Why?
|
| Sex Hormone-Binding Globulin | 1 | 2007 | 546 | 0.060 |
Why?
|
| Cell Line, Tumor | 2 | 2018 | 16905 | 0.060 |
Why?
|
| Risk Factors | 10 | 2017 | 74269 | 0.060 |
Why?
|
| Data Collection | 4 | 2002 | 3317 | 0.060 |
Why?
|
| Community Health Nursing | 1 | 2004 | 23 | 0.060 |
Why?
|
| Urethra | 2 | 2003 | 406 | 0.060 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2010 | 1132 | 0.060 |
Why?
|
| Clostridium Infections | 1 | 2011 | 557 | 0.060 |
Why?
|
| Nurse Clinicians | 1 | 2004 | 30 | 0.060 |
Why?
|
| Syndrome | 4 | 2006 | 3278 | 0.060 |
Why?
|
| Pandemics | 2 | 2022 | 8621 | 0.060 |
Why?
|
| Predictive Value of Tests | 3 | 2016 | 15273 | 0.060 |
Why?
|
| Nephrectomy | 2 | 2000 | 1017 | 0.060 |
Why?
|
| Psychological Tests | 1 | 2006 | 639 | 0.060 |
Why?
|
| Infection Control | 1 | 2011 | 983 | 0.060 |
Why?
|
| Analgesics | 1 | 2010 | 1066 | 0.060 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2008 | 3967 | 0.050 |
Why?
|
| Urinary Tract Infections | 1 | 1990 | 817 | 0.050 |
Why?
|
| Young Adult | 11 | 2021 | 58673 | 0.050 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2007 | 859 | 0.050 |
Why?
|
| Imidazoles | 1 | 2009 | 1178 | 0.050 |
Why?
|
| Indoles | 1 | 2011 | 1830 | 0.050 |
Why?
|
| Eye Diseases | 1 | 2008 | 651 | 0.050 |
Why?
|
| Hypoglycemic Agents | 1 | 2015 | 3149 | 0.050 |
Why?
|
| Leukocyte Count | 2 | 2006 | 1600 | 0.050 |
Why?
|
| Hospital Mortality | 1 | 2016 | 5420 | 0.050 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2006 | 787 | 0.050 |
Why?
|
| Drug Administration Routes | 1 | 2002 | 150 | 0.050 |
Why?
|
| Colony Count, Microbial | 1 | 2002 | 328 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2002 | 311 | 0.050 |
Why?
|
| Plasmodium falciparum | 1 | 2011 | 1741 | 0.050 |
Why?
|
| Protein Array Analysis | 3 | 2011 | 401 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2024 | 9274 | 0.050 |
Why?
|
| Rest | 1 | 2006 | 915 | 0.050 |
Why?
|
| Heart Transplantation | 1 | 2015 | 3217 | 0.050 |
Why?
|
| Scotland | 1 | 2021 | 144 | 0.050 |
Why?
|
| Myocardial Infarction | 1 | 2022 | 11891 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2002 | 430 | 0.050 |
Why?
|
| Diabetes Complications | 1 | 2008 | 1342 | 0.050 |
Why?
|
| Antigens, Neoplasm | 2 | 2006 | 1999 | 0.050 |
Why?
|
| Proteomics | 2 | 2005 | 3810 | 0.050 |
Why?
|
| Biopsy, Needle | 2 | 2007 | 1633 | 0.050 |
Why?
|
| Hospitalization | 2 | 2019 | 10761 | 0.050 |
Why?
|
| Age Distribution | 2 | 2003 | 2893 | 0.040 |
Why?
|
| Methods | 1 | 2001 | 1075 | 0.040 |
Why?
|
| Prognosis | 7 | 2024 | 29636 | 0.040 |
Why?
|
| Comorbidity | 5 | 2006 | 10552 | 0.040 |
Why?
|
| Urinary Bladder | 2 | 2003 | 1166 | 0.040 |
Why?
|
| Critical Illness | 1 | 2013 | 2709 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2022 | 17766 | 0.040 |
Why?
|
| Sinus Thrombosis, Intracranial | 1 | 2021 | 110 | 0.040 |
Why?
|
| Michigan | 1 | 2020 | 342 | 0.040 |
Why?
|
| Police | 1 | 2022 | 157 | 0.040 |
Why?
|
| Pacemaker, Artificial | 1 | 2006 | 815 | 0.040 |
Why?
|
| Estradiol | 1 | 2007 | 1932 | 0.040 |
Why?
|
| Gastric Bypass | 1 | 2008 | 826 | 0.040 |
Why?
|
| Risk Assessment | 4 | 2016 | 24086 | 0.040 |
Why?
|
| Private Practice | 1 | 2000 | 153 | 0.040 |
Why?
|
| Pressure | 1 | 2003 | 1155 | 0.040 |
Why?
|
| Evidence-Based Medicine | 2 | 2018 | 3696 | 0.040 |
Why?
|
| Cost of Illness | 2 | 2011 | 1940 | 0.040 |
Why?
|
| Prospective Studies | 10 | 2021 | 54263 | 0.040 |
Why?
|
| Pain Measurement | 2 | 2007 | 3514 | 0.040 |
Why?
|
| Life Style | 2 | 2009 | 3888 | 0.040 |
Why?
|
| Genetic Heterogeneity | 1 | 2002 | 724 | 0.040 |
Why?
|
| Emergency Service, Hospital | 1 | 2018 | 7809 | 0.040 |
Why?
|
| Depressive Disorder, Major | 1 | 2016 | 4735 | 0.040 |
Why?
|
| Urologic Surgical Procedures, Male | 1 | 1999 | 81 | 0.040 |
Why?
|
| Canada | 3 | 2010 | 2128 | 0.040 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2024 | 1790 | 0.040 |
Why?
|
| Cross-Cultural Comparison | 1 | 2001 | 632 | 0.040 |
Why?
|
| Heart Failure | 1 | 2022 | 11835 | 0.040 |
Why?
|
| Reproducibility of Results | 7 | 2016 | 20048 | 0.040 |
Why?
|
| Baltimore | 2 | 2008 | 230 | 0.040 |
Why?
|
| BRCA2 Protein | 1 | 2022 | 797 | 0.040 |
Why?
|
| Obesity, Morbid | 1 | 2008 | 1287 | 0.040 |
Why?
|
| Europe | 2 | 2020 | 3433 | 0.040 |
Why?
|
| Ileus | 1 | 2017 | 57 | 0.040 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2008 | 3159 | 0.040 |
Why?
|
| Disease Progression | 4 | 2015 | 13505 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2016 | 36247 | 0.040 |
Why?
|
| Radiotherapy Dosage | 2 | 2014 | 2897 | 0.040 |
Why?
|
| Qualitative Research | 2 | 2007 | 2958 | 0.040 |
Why?
|
| Anti-Infective Agents | 1 | 2004 | 982 | 0.040 |
Why?
|
| Utilization Review | 1 | 2018 | 383 | 0.040 |
Why?
|
| Rabbits | 1 | 2003 | 4773 | 0.040 |
Why?
|
| Translocation, Genetic | 1 | 2002 | 1388 | 0.030 |
Why?
|
| Mutation | 2 | 2020 | 29950 | 0.030 |
Why?
|
| Interviews as Topic | 1 | 2004 | 2656 | 0.030 |
Why?
|
| Mitomycin | 1 | 2017 | 262 | 0.030 |
Why?
|
| Ileostomy | 1 | 2017 | 119 | 0.030 |
Why?
|
| ROC Curve | 3 | 2016 | 3568 | 0.030 |
Why?
|
| Potassium, Dietary | 1 | 1996 | 104 | 0.030 |
Why?
|
| Korea | 1 | 2015 | 96 | 0.030 |
Why?
|
| Philippines | 1 | 2015 | 91 | 0.030 |
Why?
|
| Morbidity | 2 | 2017 | 1765 | 0.030 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2004 | 936 | 0.030 |
Why?
|
| BRCA1 Protein | 1 | 2022 | 1146 | 0.030 |
Why?
|
| Anastomotic Leak | 1 | 2017 | 164 | 0.030 |
Why?
|
| Drug Therapy | 1 | 1999 | 504 | 0.030 |
Why?
|
| Organoplatinum Compounds | 1 | 2017 | 410 | 0.030 |
Why?
|
| Intubation, Gastrointestinal | 1 | 2016 | 169 | 0.030 |
Why?
|
| Disease-Free Survival | 2 | 2024 | 6830 | 0.030 |
Why?
|
| Mucin-4 | 1 | 2015 | 33 | 0.030 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2001 | 867 | 0.030 |
Why?
|
| Vietnam | 1 | 2015 | 411 | 0.030 |
Why?
|
| Health Status Disparities | 2 | 2022 | 1819 | 0.030 |
Why?
|
| Prostatic Diseases | 1 | 1995 | 57 | 0.030 |
Why?
|
| Diet, Sodium-Restricted | 1 | 1996 | 291 | 0.030 |
Why?
|
| Serum | 2 | 2006 | 211 | 0.030 |
Why?
|
| Colon, Sigmoid | 1 | 2015 | 124 | 0.030 |
Why?
|
| Health Status | 2 | 2007 | 4081 | 0.030 |
Why?
|
| Germ-Line Mutation | 1 | 2022 | 1843 | 0.030 |
Why?
|
| Patient-Centered Care | 1 | 2004 | 1416 | 0.030 |
Why?
|
| Intraoperative Care | 1 | 2017 | 768 | 0.030 |
Why?
|
| Depressive Disorder | 1 | 2006 | 3728 | 0.030 |
Why?
|
| Oncolytic Viruses | 1 | 2017 | 343 | 0.030 |
Why?
|
| Health Services Accessibility | 2 | 2008 | 5396 | 0.030 |
Why?
|
| Hearing Loss, Bilateral | 1 | 1993 | 53 | 0.030 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2004 | 12281 | 0.030 |
Why?
|
| Ear | 1 | 2013 | 172 | 0.030 |
Why?
|
| Psychometrics | 4 | 2007 | 3049 | 0.030 |
Why?
|
| Hospitals | 2 | 2020 | 3929 | 0.030 |
Why?
|
| Urine | 2 | 2006 | 363 | 0.030 |
Why?
|
| Magnesium | 1 | 1996 | 810 | 0.030 |
Why?
|
| Pilot Projects | 2 | 2022 | 8553 | 0.030 |
Why?
|
| Sodium, Dietary | 1 | 1996 | 425 | 0.030 |
Why?
|
| Esophagectomy | 1 | 2016 | 469 | 0.030 |
Why?
|
| Leadership | 1 | 2022 | 1372 | 0.030 |
Why?
|
| Evaluation Studies as Topic | 2 | 1993 | 1628 | 0.030 |
Why?
|
| Lymphatic System | 1 | 2013 | 254 | 0.030 |
Why?
|
| Survival Analysis | 2 | 2015 | 10185 | 0.030 |
Why?
|
| Boston | 3 | 2011 | 9282 | 0.020 |
Why?
|
| Carcinoma | 1 | 2003 | 2334 | 0.020 |
Why?
|
| Hypertension | 2 | 2006 | 8595 | 0.020 |
Why?
|
| Depression | 1 | 2011 | 8033 | 0.020 |
Why?
|
| Delayed-Action Preparations | 2 | 2006 | 961 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2003 | 3613 | 0.020 |
Why?
|
| Japan | 1 | 2015 | 1369 | 0.020 |
Why?
|
| Health Education | 2 | 2008 | 1049 | 0.020 |
Why?
|
| Case-Control Studies | 2 | 2021 | 22041 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2017 | 1897 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2017 | 3605 | 0.020 |
Why?
|
| Cisplatin | 1 | 2017 | 1642 | 0.020 |
Why?
|
| Decontamination | 1 | 2011 | 72 | 0.020 |
Why?
|
| Endemic Diseases | 1 | 2011 | 191 | 0.020 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2018 | 951 | 0.020 |
Why?
|
| Antibodies, Protozoan | 1 | 2011 | 250 | 0.020 |
Why?
|
| Treatment Failure | 2 | 2008 | 2646 | 0.020 |
Why?
|
| Staining and Labeling | 1 | 2015 | 1090 | 0.020 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2020 | 2052 | 0.020 |
Why?
|
| Malaria Vaccines | 1 | 2011 | 164 | 0.020 |
Why?
|
| Physical Examination | 2 | 2008 | 1244 | 0.020 |
Why?
|
| Focus Groups | 2 | 2007 | 1372 | 0.020 |
Why?
|
| Confidence Intervals | 2 | 2007 | 2932 | 0.020 |
Why?
|
| Cross-Sectional Studies | 4 | 2020 | 25928 | 0.020 |
Why?
|
| Internet | 1 | 2002 | 3074 | 0.020 |
Why?
|
| Combined Modality Therapy | 3 | 2017 | 8551 | 0.020 |
Why?
|
| Natural Language Processing | 1 | 2018 | 1136 | 0.020 |
Why?
|
| China | 1 | 2015 | 2340 | 0.020 |
Why?
|
| Neurofibromatosis 2 | 1 | 1993 | 385 | 0.020 |
Why?
|
| Interferon-beta | 1 | 1991 | 345 | 0.020 |
Why?
|
| Antigens, Protozoan | 1 | 2011 | 315 | 0.020 |
Why?
|
| Primary Health Care | 2 | 2004 | 4649 | 0.020 |
Why?
|
| Kenya | 1 | 2011 | 749 | 0.020 |
Why?
|
| Agranulocytosis | 1 | 1988 | 99 | 0.020 |
Why?
|
| Cell Adhesion Molecules | 1 | 2015 | 1602 | 0.020 |
Why?
|
| Hospitals, University | 1 | 2010 | 568 | 0.020 |
Why?
|
| Adolescent | 9 | 2021 | 87747 | 0.020 |
Why?
|
| Bone Marrow Transplantation | 1 | 1996 | 2696 | 0.020 |
Why?
|
| Radiometry | 1 | 2014 | 813 | 0.020 |
Why?
|
| Killer Cells, Natural | 1 | 2017 | 2204 | 0.020 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2002 | 4044 | 0.020 |
Why?
|
| Speech Perception | 1 | 1993 | 505 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2015 | 1408 | 0.020 |
Why?
|
| Postoperative Period | 1 | 1993 | 1821 | 0.020 |
Why?
|
| Nutritional Status | 1 | 2016 | 1606 | 0.020 |
Why?
|
| Neuroblastoma | 1 | 1996 | 1252 | 0.020 |
Why?
|
| Propensity Score | 1 | 2015 | 1918 | 0.020 |
Why?
|
| Animals | 3 | 2017 | 167940 | 0.020 |
Why?
|
| Office Visits | 2 | 2004 | 597 | 0.020 |
Why?
|
| Interferon Type I | 1 | 1991 | 559 | 0.020 |
Why?
|
| Registries | 1 | 2024 | 8449 | 0.020 |
Why?
|
| International Cooperation | 2 | 2004 | 1436 | 0.020 |
Why?
|
| Species Specificity | 1 | 2011 | 2413 | 0.020 |
Why?
|
| Odds Ratio | 2 | 2011 | 9712 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 2 | 2011 | 6131 | 0.020 |
Why?
|
| Social Support | 2 | 2007 | 2145 | 0.020 |
Why?
|
| Administration, Oral | 1 | 1995 | 4044 | 0.020 |
Why?
|
| Tissue and Organ Procurement | 1 | 2015 | 944 | 0.020 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2002 | 3606 | 0.020 |
Why?
|
| Socioeconomic Factors | 2 | 2015 | 7803 | 0.020 |
Why?
|
| Diagnostic Techniques, Urological | 1 | 2006 | 28 | 0.020 |
Why?
|
| Bone Marrow | 1 | 1997 | 2918 | 0.020 |
Why?
|
| Hydrogels | 1 | 2012 | 725 | 0.020 |
Why?
|
| Ureteral Diseases | 1 | 1986 | 65 | 0.020 |
Why?
|
| Health Care Costs | 1 | 2019 | 3257 | 0.020 |
Why?
|
| Radiography | 2 | 2015 | 6965 | 0.020 |
Why?
|
| Urethritis | 1 | 2005 | 24 | 0.020 |
Why?
|
| Carbocyanines | 1 | 2006 | 174 | 0.020 |
Why?
|
| Consumer Health Information | 1 | 2008 | 209 | 0.020 |
Why?
|
| Ultrasonography, Interventional | 1 | 2014 | 1503 | 0.020 |
Why?
|
| Chemical Fractionation | 1 | 2005 | 62 | 0.020 |
Why?
|
| Patient Admission | 1 | 2013 | 1384 | 0.020 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2011 | 2569 | 0.020 |
Why?
|
| Anions | 1 | 2005 | 137 | 0.020 |
Why?
|
| Prostatic Intraepithelial Neoplasia | 1 | 2005 | 81 | 0.020 |
Why?
|
| HIV Infections | 1 | 2011 | 17159 | 0.020 |
Why?
|
| Risk | 2 | 2009 | 9629 | 0.020 |
Why?
|
| Calgranulin B | 1 | 2005 | 86 | 0.020 |
Why?
|
| Heart Arrest | 1 | 2015 | 1506 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 2852 | 0.020 |
Why?
|
| Patient Care Planning | 2 | 2004 | 909 | 0.020 |
Why?
|
| Body Fluids | 1 | 2006 | 319 | 0.010 |
Why?
|
| Norway | 1 | 2006 | 497 | 0.010 |
Why?
|
| Direct Service Costs | 1 | 2004 | 60 | 0.010 |
Why?
|
| Principal Component Analysis | 1 | 2007 | 939 | 0.010 |
Why?
|
| Discriminant Analysis | 1 | 2004 | 223 | 0.010 |
Why?
|
| Factor Analysis, Statistical | 1 | 2007 | 998 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2015 | 4002 | 0.010 |
Why?
|
| Haptoglobins | 1 | 2005 | 167 | 0.010 |
Why?
|
| Anger | 1 | 2006 | 401 | 0.010 |
Why?
|
| Feeding Behavior | 1 | 1996 | 3185 | 0.010 |
Why?
|
| Serpins | 1 | 2005 | 247 | 0.010 |
Why?
|
| Transforming Growth Factor beta | 1 | 1991 | 1956 | 0.010 |
Why?
|
| Immunoprecipitation | 1 | 2006 | 877 | 0.010 |
Why?
|
| Gene Expression | 1 | 2016 | 7592 | 0.010 |
Why?
|
| Prejudice | 1 | 2007 | 563 | 0.010 |
Why?
|
| Neutropenia | 1 | 1988 | 884 | 0.010 |
Why?
|
| Malaria, Falciparum | 1 | 2011 | 1076 | 0.010 |
Why?
|
| Professional Practice | 2 | 1995 | 313 | 0.010 |
Why?
|
| Carcinoma, Renal Cell | 1 | 1998 | 3217 | 0.010 |
Why?
|
| Hematoma | 1 | 2008 | 769 | 0.010 |
Why?
|
| Iodine Radioisotopes | 1 | 1986 | 1032 | 0.010 |
Why?
|
| Absenteeism | 1 | 2004 | 250 | 0.010 |
Why?
|
| Algorithms | 2 | 2018 | 13967 | 0.010 |
Why?
|
| Chromosome Breakage | 1 | 2002 | 159 | 0.010 |
Why?
|
| Nurse's Role | 1 | 2003 | 188 | 0.010 |
Why?
|
| Research Design | 1 | 1998 | 6181 | 0.010 |
Why?
|
| Cytogenetic Analysis | 1 | 2002 | 271 | 0.010 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2003 | 508 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 1991 | 6543 | 0.010 |
Why?
|
| Guidelines as Topic | 1 | 2008 | 1395 | 0.010 |
Why?
|
| Vasodilation | 1 | 2006 | 964 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2002 | 311 | 0.010 |
Why?
|
| Translations | 1 | 2001 | 81 | 0.010 |
Why?
|
| Chromatography, Liquid | 1 | 2005 | 987 | 0.010 |
Why?
|
| Surgical Procedures, Operative | 1 | 1993 | 1919 | 0.010 |
Why?
|
| Linear Models | 1 | 2011 | 5876 | 0.010 |
Why?
|
| Family Practice | 1 | 2004 | 512 | 0.010 |
Why?
|
| Fever | 1 | 1988 | 1618 | 0.010 |
Why?
|
| Otitis Media | 1 | 2003 | 285 | 0.010 |
Why?
|
| Health Services Research | 1 | 2008 | 1811 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2005 | 2509 | 0.010 |
Why?
|
| Facial Nerve | 1 | 2003 | 277 | 0.010 |
Why?
|
| Educational Status | 1 | 2008 | 2512 | 0.010 |
Why?
|
| Placebos | 1 | 2004 | 1672 | 0.010 |
Why?
|
| Cross-Over Studies | 1 | 2006 | 2061 | 0.010 |
Why?
|
| Blood Proteins | 1 | 2005 | 1172 | 0.010 |
Why?
|
| Blood Pressure Determination | 1 | 2004 | 641 | 0.010 |
Why?
|
| Ambulatory Care | 2 | 2003 | 2783 | 0.010 |
Why?
|
| Semen | 1 | 2002 | 346 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 2011 | 4546 | 0.010 |
Why?
|
| Intensive Care Units | 1 | 2013 | 3737 | 0.010 |
Why?
|
| Cluster Analysis | 1 | 2006 | 2698 | 0.010 |
Why?
|
| Phytotherapy | 1 | 2001 | 295 | 0.010 |
Why?
|
| Urban Population | 1 | 2007 | 2021 | 0.010 |
Why?
|
| Lasers | 1 | 2003 | 952 | 0.010 |
Why?
|
| Probability | 1 | 2005 | 2476 | 0.010 |
Why?
|
| Disability Evaluation | 1 | 2006 | 1826 | 0.010 |
Why?
|
| Abscess | 1 | 1983 | 605 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2006 | 3804 | 0.010 |
Why?
|
| Interpersonal Relations | 1 | 2006 | 1430 | 0.010 |
Why?
|
| Body Mass Index | 2 | 2008 | 12901 | 0.010 |
Why?
|
| Reference Values | 1 | 2006 | 4920 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2006 | 5039 | 0.010 |
Why?
|
| Lung Diseases | 1 | 1988 | 1915 | 0.010 |
Why?
|
| Epinephrine | 1 | 2001 | 791 | 0.010 |
Why?
|
| Mass Spectrometry | 1 | 2005 | 2192 | 0.010 |
Why?
|
| Fluorescent Dyes | 1 | 2006 | 1914 | 0.010 |
Why?
|
| Bacterial Infections | 1 | 2006 | 1402 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2006 | 4900 | 0.010 |
Why?
|
| Vasoconstrictor Agents | 1 | 2001 | 651 | 0.010 |
Why?
|
| Patient Compliance | 1 | 2008 | 2689 | 0.010 |
Why?
|
| Guideline Adherence | 1 | 2008 | 2283 | 0.010 |
Why?
|
| Microsurgery | 1 | 2003 | 791 | 0.010 |
Why?
|
| Gene Rearrangement | 1 | 2002 | 1122 | 0.010 |
Why?
|
| Mental Health | 1 | 2011 | 3206 | 0.010 |
Why?
|
| Weight Loss | 1 | 2008 | 2683 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2005 | 8945 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 1990 | 5507 | 0.010 |
Why?
|
| Bone Marrow Purging | 1 | 1996 | 108 | 0.010 |
Why?
|
| Radiotherapy | 1 | 2003 | 1505 | 0.010 |
Why?
|
| Abdomen | 1 | 1983 | 1124 | 0.010 |
Why?
|
| Cell Line | 2 | 2006 | 15626 | 0.010 |
Why?
|
| Retirement | 1 | 1998 | 199 | 0.010 |
Why?
|
| Bone Marrow Neoplasms | 1 | 1997 | 101 | 0.010 |
Why?
|
| Regression Analysis | 2 | 1996 | 6361 | 0.010 |
Why?
|
| Health Behavior | 1 | 2007 | 2621 | 0.010 |
Why?
|
| Endoscopy | 1 | 1986 | 1841 | 0.010 |
Why?
|
| Personnel Selection | 1 | 1998 | 193 | 0.010 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2001 | 1256 | 0.010 |
Why?
|
| United States Agency for Healthcare Research and Quality | 1 | 1995 | 87 | 0.010 |
Why?
|
| Bacteria | 1 | 2006 | 2196 | 0.010 |
Why?
|
| Flutamide | 1 | 1995 | 95 | 0.010 |
Why?
|
| Sex Factors | 1 | 2009 | 10530 | 0.010 |
Why?
|
| Nervous System Diseases | 1 | 2005 | 1647 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2017 | 13629 | 0.010 |
Why?
|
| Consensus | 1 | 2004 | 3106 | 0.010 |
Why?
|
| Blood Loss, Surgical | 1 | 1998 | 657 | 0.010 |
Why?
|
| Acute Disease | 1 | 2005 | 7268 | 0.010 |
Why?
|
| HIV-1 | 1 | 2011 | 6850 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2006 | 10829 | 0.010 |
Why?
|
| Patient Education as Topic | 1 | 2003 | 2311 | 0.010 |
Why?
|
| Physician-Patient Relations | 1 | 2006 | 3242 | 0.010 |
Why?
|
| Individuality | 1 | 1995 | 300 | 0.010 |
Why?
|
| Models, Statistical | 1 | 2007 | 5073 | 0.010 |
Why?
|
| Smoking Cessation | 1 | 2004 | 2064 | 0.010 |
Why?
|
| Repressor Proteins | 1 | 2002 | 2978 | 0.010 |
Why?
|
| Base Sequence | 1 | 2002 | 12447 | 0.010 |
Why?
|
| Transplantation, Autologous | 1 | 1996 | 2120 | 0.010 |
Why?
|
| Stress, Psychological | 1 | 2006 | 4440 | 0.010 |
Why?
|
| Infant | 3 | 2002 | 36030 | 0.010 |
Why?
|
| Massachusetts | 1 | 2003 | 8805 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2002 | 17628 | 0.010 |
Why?
|
| Pain, Postoperative | 1 | 2000 | 1718 | 0.010 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 1995 | 1153 | 0.010 |
Why?
|
| Bone Marrow Cells | 1 | 1997 | 2424 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2006 | 9196 | 0.010 |
Why?
|
| Blood Glucose | 1 | 2003 | 6375 | 0.010 |
Why?
|
| Proteins | 1 | 2003 | 6030 | 0.000 |
Why?
|
| Epidermal Growth Factor | 1 | 1991 | 695 | 0.000 |
Why?
|
| Inflammation | 1 | 2007 | 10757 | 0.000 |
Why?
|
| Cell Count | 1 | 1991 | 1838 | 0.000 |
Why?
|
| DNA-Binding Proteins | 1 | 2002 | 9590 | 0.000 |
Why?
|
| Endoscopes | 1 | 1986 | 168 | 0.000 |
Why?
|
| Ureteral Neoplasms | 1 | 1986 | 110 | 0.000 |
Why?
|
| Dilatation | 1 | 1986 | 307 | 0.000 |
Why?
|
| Ureteral Obstruction | 1 | 1986 | 292 | 0.000 |
Why?
|
| Attitude of Health Personnel | 1 | 1995 | 3870 | 0.000 |
Why?
|
| Child, Preschool | 2 | 1996 | 42034 | 0.000 |
Why?
|
| Neoplasms | 1 | 1988 | 22066 | 0.000 |
Why?
|
| Child | 3 | 1996 | 79758 | 0.000 |
Why?
|
| Drainage | 1 | 1983 | 1161 | 0.000 |
Why?
|
| Cells, Cultured | 1 | 1991 | 18968 | 0.000 |
Why?
|
| Infant, Newborn | 1 | 1988 | 26168 | 0.000 |
Why?
|